Irregular application or early termination of treatment increases the risk of relapse. The duration of therapy can be influenced by factors such as the presence of concomitant diseases, the state of the nails at the beginning of the course of treatment.
If after 2 weeks of treatment there is no improvement, it is necessary to re-determine the causative agent of the disease and its sensitivity to the drug.
Systemic use in onychomycosis is justified only at the total defeat of most nails, the presence of pronounced subungual hyperkeratosis, ineffectiveness of previous local therapy.
In the treatment of onychomycosis, the clinical response is usually observed a few months after mycological cure and discontinuation of treatment, which is due to the rate of regrowth of a healthy nail. Removal of nail plates in the treatment of onychomycosis of brushes for 3 weeks and onychomycosis of the feet for 6 weeks is not required.
In the presence of liver disease, terbinafine clearance can be reduced.
During treatment, it is necessary to monitor the level of hepatic transaminases in the serum. In rare cases, after 3 months of treatment, there is cholestasis and hepatitis. If there are signs of impaired liver function (weakness, persistent nausea, loss of appetite, abdominal pain, jaundice, darkening of the urine or colorless stools), the drug should be discarded.
The administration of terbinafine to psoriasis patients requires increased discretion;in very rare cases terbinafine can trigger an outbreak of psoriasis.
When treating terbinafine, general hygiene rules should be followed to prevent the possibility of re-infection through linen and shoes. In the process of treatment (after 2 weeks), as well as at the end of treatment, it is necessary to produce antifungal treatment of shoes, socks and stockings.